Using Boston-based Current Health’s FDA-cleared remote monitoring sensors and platform, experts from the company and Mayo Clinic can expedite the identification of the coronavirus and improve treatment efficacy and care for patients with or at risk of infection.
The collaboration is set up to identify those with the virus, then predict symptom and disease severity in patients, healthcare workers and other at-risk individuals in critical service sectors.
Current Health intends to use digital biomarkers like temperature, heart rate, oxygen saturation, activity and posture, all of which are collected by its patient monitoring platforms, to develop artificial intelligence-based algorithms that detect and predict symptom and disease severity.
Through the collaboration, Current Health and Mayo Clinic hope to scale data analytics, add to the hospital’s advancements in accelerating COVID-19 detection and diagnosis, and improve efforts to understand and treat the disease. Mayo Clinic is also set to become an investor in Current Health as part of the collaboration.
“Our collective ability to save lives hinges on our ability to understand this virus quickly,” Current Health CEO & co-founder Chris McCann said in a news release. “COVID-19 has presented in many ways across different people, which has made it very challenging to understand the virus and how it develops.
“By combining our platform with the deep medical and scientific expertise that exists at Mayo Clinic, we seek to explore both known and novel biomarkers, as well as how they manifest in entirely diverse populations. This will be critical to determining how we define, and enable effective treatment of, this disease.”